Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after large swings related to its COVID-19 vaccine.
Pfizer shares, which had risen Tuesday morning after improved demand for the Covid vaccine, dropped 2.3% after Kennedy's ...
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...
After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely ...
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...
"Pfizer just released its list of side effects of its COVID-19 vaccine," multiple Facebook posts said Jan. 26 and 27. The posts included a purported list of 46 Pfizer-BioNtech COVID-19 vaccine side ...
Pfizer Inc. (NYSE:PFE), one of the world's largest pharmaceutical companies with a market capitalization of $151.25 billion, finds itself at a critical juncture as it navigates the post-pandemic ...
Idaho Sen. Brandon Shippy proposes bill to ban mRNA vaccines until 2035 by incorrectly categorizing them as gene therapy, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback